Kaynaklar
1.Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72.2.Perez-Vargas J, Isa P, Lopez S, Aries CF. Rotavirus vaccine: Early introduction in Latin America-risks and benefits. Arch Med 2006; 37:1-10.3.Fischer TK, Bresee JS, Glass RI. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine 2004; 22:(suppl 1):S49-54.4.Pickering LK. Approach to diagnosis and manangement of gastrointestinal tract infections.In: Long S, Pickering LK (eds) Principle and Practise of Pediatric Infectious Diseases. Churchill Livingstone, New York; 1997. p.410-8. 5.Ceyhan M, Kanra G, Yeniay I, Ciliv G, Vesikari T. Rotaviruses in infants with diarrhea studied by viral RNA electrophoresis in Ankara, Turkey. Turk J Pediatr 1987; 29:145-9.6.Cataloluk O, Iturriza M, Gray J. Molecular characterization of rotaviruses circulating in the population in Turkey. Epidemiol Infect 2005; 133(4):673-8.7.Karadag A, Acikgoz ZA, Avci Z, et al. Childhood diarrhea in Ankara, Turkey: Epidemiological and clinical features of rotavirus-positive versus rotavirus-negative cases. Scand J Infect Dis 2005; 37: 269-75.8.Vesikari T, Isolauri E, Delem A, DHondt E, Andre FE, Zissis G. Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT4237 in adults and young children. Lancet 1983; 2:807-11.9.Lanata CF, Black RE, Flores J, et al. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. Vaccine 1996; 14: 237-43.10.Vesikari T, Ruuska T, Green KY, Flores JI Kapikian AZ. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassotant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. Pediatr Infect Dis J 1992; 11: 535-42.11.Perez-Schael I, Blanco M, Vilar M, et al. Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants. J Clin Microbiol 1990; 28:553-8.12.Advisory Committee on Immunization Practices. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1-20.13.Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344: 564-72.14.Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999; 17: 2207-22.15.Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350:1205-9.16.Clark HF, Borian FE, Bell LM, Modesto K, Gouvea, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988; 158:570-87.17.Clark HF, Offit PA, Ellis RW, et al. WC3 reassortant vaccines in children. Arch Virol 1996;(Suppl 12):S73-80.18.Wood D. WHO informal consultation on quality, safety and efficacy specifications for live attenuated rotavirus vaccines Mexico City, Mexico, 8-9 February 2005. Vaccine 2005; 23:5478-87.19.Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 2005; 24: 481-8.20.Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937-43.
